SCHEMBL5467390

SCHEMBL5467390

CC(C)(C)[Si](C)(C)OCCOc1ccc(Cl)c([N+](=O)[O-])c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
RAF1 P04049 1/20 0.44
GFER P55789 1/20 0.44
PAX8 Q06710 1/20 0.44
VCAM1 P19320 6/20 0.40
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
RECQL P46063 1/20 0.38
HSP90AA1 P07900 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
THRB P10828 1/20 0.38
DHFR P00374 1/20 0.38
S1PR4 O95977 1/20 0.38
ALPL P05186 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466473 0.93 MAPT (0.47) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL5469275 0.86 MAPT (0.43) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL5455878 0.84 MAPT (0.55) MAPTMAPK1ALDH1A1LMNAKMT2A
SCHEMBL221664 0.81 KMT2A (0.48) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL27087776 0.81 LMNA (0.47) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL5455966 0.81 AR (0.44) MAPTCYP3A4
SCHEMBL15814033 0.79 MAPT (0.51) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL14290088 0.78 MAPT (0.64) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL9513657 0.78 MAPT (0.56) MAPTMAPK1ALDH1A1HPGDLMNA
SCHEMBL5466698 0.78 DRD4 (0.45) MAPTALDH1A1LMNANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885MAPK1 1466/4885ALDH1A1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.